Oncotarget

Research Papers:

Identification and validation of differentially expressed proteins in epithelial ovarian cancers using quantitative proteomics

Hong Qu _, Yuling Chen, Guangming Cao, Chongdong Liu, Jiatong Xu, Haiteng Deng and Zhenyu Zhang

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:83187-83199. https://doi.org/10.18632/oncotarget.13077

Metrics: PDF 1027 views  |   HTML 1800 views  |   ?  


Abstract

Hong Qu1,*, Yuling Chen2,3,*, Guangming Cao1, Chongdong Liu1, Jiatong Xu3, Haiteng Deng3, Zhenyu Zhang1

1Department of Obstetrics & Gynecology, Beijing Chao-yang Hospital Affiliated to Capital Medical University, Beijing, China

2Tsinghua University-Peking University Joint Center for Life Sciences, Beijing, China

3MOE Key Laboratory of Bioinformatics, School of Life Sciences, Tsinghua University, Beijing, China

*These authors have contributed equally to this work

Correspondence to:

Zhenyu Zhang, email: zhenyuzhang2000@163.com

Haiteng Deng, email: dht@mail.tsinghua.edu.cn

Keywords: proteomics, epithelial ovarian cancer, CLIC1, LGALS3BP, therapeutic target

Received: May 02, 2016    Accepted: October 19, 2016    Published: November 4, 2016

ABSTRACT

Ovarian cancer is the most lethal gynecological malignant tumor because of its high recurrence rate. In the present work, in order to find new therapeutic targets, we identified 8480 proteins in thirteen pairs of ovarian cancer tissues and normal ovary tissues through quantitative proteomics. 498 proteins were found to be differentially expressed in ovarian cancer, which involved in various cellular processes, including metabolism, response to stimulus and biosynthetic process. The expression levels of chloride intracellular channel protein 1 (CLIC1) and lectin galactoside-binding soluble 3 binding protein (LGALS3BP) in epithelial ovarian cancer tissues were significantly higher than those in normal ovary tissues as confirmed by western blotting and immunohistochemistry. The knockdown of CLIC1 in A2780 cell line downregulated expression of CTPS1, leading to the decrease of CTP and an arrest of cell cycle G1 phase, which results into a slower proliferation. CLIC1-knockdown can also slow down the tumor growth in vivo. Besides, CLIC1-knockdown cells showed an increased sensitivity to hydrogen peroxide and cisplatin, suggesting that CLIC1 was involved in regulation of redox and drug resistance in ovarian cancer cells. These results indicate CLIC1 promotes tumorgenesis, and is a potential therapeutic target in epithelial ovarian cancer treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13077